KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Gains from Investment Securities fell 739.33% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 739.33%. This contributed to the annual value of $331000.0 for FY2024, which is 9029.79% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Gains from Investment Securities is $1.4 million, which was down 739.33% from $1.4 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $13.1 million during Q3 2023, with a 5-year trough of -$510000.0 in Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median Gains from Investment Securities value was $1.5 million (recorded in 2024), while the average stood at $5.1 million.
  • Over the last 5 years, Rigel Pharmaceuticals' Gains from Investment Securities had its largest YoY gain of 166923.08% in 2022, and its largest YoY loss of 840000.0% in 2022.
  • Rigel Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $39000.0 in 2021, then soared by 1669.23% to $690000.0 in 2022, then crashed by 84.78% to $105000.0 in 2023, then skyrocketed by 1347.96% to $1.5 million in 2024, then decreased by 7.39% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.4 million for Q2 2025, and $605514.0 during Q1 2025.